Project Veritas publishes Pfizer Whistleblower LEAKS executive emails EXPOSING Suppression of Covid Vax Info From Public
She leaked internal emails that show corporate executives telling staff to be secretive about the use of human fetal tissue in laboratory testing of the COVID vaccine.
Here are some of the highlights from today’s video:
Vanessa Gelman, Pfizer Senior Director of Worldwide Research: “From the perspective of corporate affairs, we want to avoid having the information on fetal cells floating out there…The risk of communicating this right now outweighs any potential benefit we could see, particularly with general members of the public who may take this information and use it in ways we may not want out there. We have not received any questions from policymakers or media on this issue in the last few weeks, so we want to avoid raising this if possible.”
Gelman: “We have been trying as much as possible to not mention the fetal cell lines…One or more cell lines with an origin that can be traced back to human fetal tissue have been used in laboratory tests associated with the vaccine program.”
Philip Dormitzer, Pfizer Chief Scientific Officer: “HEK293T cells, used for the IVE assay, are ultimately derived from an aborted fetus. On the other hand, the Vatican doctrinal committee has confirmed that they consider it acceptable for Pro-Life believers to be immunized. Pfizer’s official statement couches the answer well and is what should be provided in response to an outside inquiry.”
Melissa Strickler, Pfizer Insider and Manufacturing Quality Auditor: “They’re being so deceptive in their emails, it’s almost like it is in the final vaccine. It just made me not trust it.”
These are shocking revelations coming from a Brave Big Pharma Insider.
The public has a right to know how the products they consume are developed, especially vaccines.
Project Veritas encourages more whistleblowers working inside Big Pharma to come forward with newsworthy information on the COVID vaccine.
Religious exemptions are being denied.
